Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 1/20 | 0.49 |
| ▸ | PLG | P00747 | 1/20 | 0.48 |
| ▸ | PLAT | P00750 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3515654 | 1.00 | GBA1 (0.53) | GBA1L3MBTL1CYP2C9CYP2C19HTR2B | |
| SCHEMBL26144434 | 0.89 | AKR1C3 (0.51) | GBA1L3MBTL1CYP2C9CYP2C19HTR2B | |
| SCHEMBL19612576 | 0.85 | CYP2C9 (0.52) | GBA1CYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL11590207 | 0.84 | GRIK1 (0.53) | MEN1KMT2AALDH1A1GAAPLG | |
| SCHEMBL2027845 | 0.83 | GBA1 (0.71) | GBA1ALDH1A1CCR3 | |
| SCHEMBL674276 | 0.83 | GBA1 (0.71) | GBA1ALDH1A1CCR3 | |
| SCHEMBL28728830 | 0.83 | ALDH1A1 (0.46) | GBA1CYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL7810455 | 0.82 | GRIN2B (0.46) | GBA1L3MBTL1CYP2C9CYP2C19HTR2B | |
| SCHEMBL2165582 | 0.82 | ALDH1A1 (0.52) | L3MBTL1CYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL7814243 | 0.81 | POLB (0.54) | L3MBTL1ALDH1A1GAAPOLBPLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185007-B1 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | GIVAUDAN SA (CH) | 2018-05-23 | — | — | EP | claimed |
| US-20160205978-A1 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | GIVAUDAN SA (CH) | 2016-07-21 | — | — | US | claimed |
| US-20100311786-A1 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | GIVAUDAN SA (CH) | 2010-12-09 | — | — | US | claimed |
| EP-2185007-A2 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | Givaudan SA (CH) | 2010-05-19 | — | — | EP | claimed |
| WO-2009015504-A2 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | GIVAUDAN SA (CH) | 2009-02-05 | — | — | WO | claimed |
| US-20250091983-A1 | CYCLOPENTANE AND CYCLOHEXANE VARIANTS OF 6-PHENYLHEXANAMIDE MITOFUSIN ACTIVATORS AND METHODS FOR USE THEREOF | MITOCHONDRIA EMOTION, INC. (US) | 2025-03-20 | — | — | US | disclosed |
| WO-2023014828-A2 | CYCLOPENTANE AND CYCLOHEXANE VARIANTS OF 6-PHENYLHEXANAMIDE MITOFUSIN ACTIVATORS AND METHODS FOR USE THEREOF | MITOCHONDRIA EMOTION, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-10172378-B2 | Mono- or bicyclic carboxylic acids as off-note blockers | GIVAUDAN, SA (CH) | 2019-01-08 | — | — | US | disclosed |
| US-10172378-B2 | Mono- or bicyclic carboxylic acids as off-note blockers | GIVAUDAN, SA (CH) | 2019-01-08 | — | — | US | disclosed |
| EP-2185007-B1 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | GIVAUDAN SA (CH) | 2018-05-23 | — | — | EP | disclosed |
| EP-2185007-B1 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | GIVAUDAN SA (CH) | 2018-05-23 | — | — | EP | disclosed |
| US-20160205978-A1 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | GIVAUDAN SA (CH) | 2016-07-21 | — | — | US | disclosed |
| EP-2185007-A2 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | Givaudan SA (CH) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009015504-A2 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | GIVAUDAN SA (CH) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009015504-A2 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | GIVAUDAN SA (CH) | 2009-02-05 | — | — | WO | disclosed |
| EP-0681569-B1 | SPIROCYCLOALKYL-SUBSTITUTED AZETIDINONES USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | SCHERING CORP (US) | 2001-03-21 | — | — | EP | disclosed |
| US-5698548-A | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents | SCHERING CORPORATION (US) | 1997-12-16 | — | — | US | disclosed |
| CN-1118163-A | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents | SCHERING CORP (US) | 1996-03-06 | — | — | CN | disclosed |
| EP-0681569-A1 | SPIROCYCLOALKYL-SUBSTITUTED AZETIDINONES USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | SCHERING CORPORATION (US) | 1995-11-15 | — | — | EP | disclosed |
| WO-1994017038-A1 | SPIROCYCLOALKYL-SUBSTITUTED AZETIDINONES USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | SCHERING CORPORATION (US) | 1994-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311786-A1 | MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS | SORD, GLUL, ASNS | GBA1 378/4885L3MBTL1 4614/4885CYP2C9 2561/4885 |
| US-20250091983-A1 | CYCLOPENTANE AND CYCLOHEXANE VARIANTS OF 6-PHENYLHEXANAMIDE MITOFUSIN ACTIVATORS AND METHODS FOR USE THEREOF | COQ8A, PDF, HAGH | GBA1 223/4885L3MBTL1 3525/4885CYP2C9 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.